131 related articles for article (PubMed ID: 20926034)
21. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
[TBL] [Abstract][Full Text] [Related]
22. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.
Beck BH; Kim HG; Kim H; Samuel S; Liu Z; Shrestha R; Haines H; Zinn K; Lopez RD
Breast Cancer Res Treat; 2010 Jul; 122(1):135-44. PubMed ID: 19763820
[TBL] [Abstract][Full Text] [Related]
23. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
24. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors.
Ferrarini M; Heltai S; Pupa SM; Mernard S; Zocchi R
J Natl Cancer Inst; 1996 Apr; 88(7):436-41. PubMed ID: 8618235
[TBL] [Abstract][Full Text] [Related]
25. A novel antibody-like TCRγδ-Ig fusion protein exhibits antitumor activity against human ovarian carcinoma.
Zheng J; Guo Y; Ji X; Cui L; He W
Cancer Lett; 2013 Dec; 341(2):150-8. PubMed ID: 23920126
[TBL] [Abstract][Full Text] [Related]
26. Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.
Liu Z; Guo BL; Gehrs BC; Nan L; Lopez RD
J Urol; 2005 May; 173(5):1552-6. PubMed ID: 15821484
[TBL] [Abstract][Full Text] [Related]
27. Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
Polito VA; Cristantielli R; Weber G; Del Bufalo F; Belardinilli T; Arnone CM; Petretto A; Antonucci L; Giorda E; Tumino N; Pitisci A; De Angelis B; Quintarelli C; Locatelli F; Caruana I
Front Immunol; 2019; 10():2717. PubMed ID: 31824502
[TBL] [Abstract][Full Text] [Related]
28. Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation.
Otto M; Barfield RC; Iyengar R; Gatewood J; Müller I; Holladay MS; Houston J; Leung W; Handgretinger R
J Immunother; 2005; 28(1):73-8. PubMed ID: 15614047
[TBL] [Abstract][Full Text] [Related]
29. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
[TBL] [Abstract][Full Text] [Related]
30. [Development of HPV16 positive cervical cancer model in the hu-PBL-SCID mouse and its immunological features].
Liang ZX; Cheng Q; Chen HZ; Xie X; Ye DF
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(17):1465-9. PubMed ID: 15500747
[TBL] [Abstract][Full Text] [Related]
31. IL-33-expanded human Vγ9Vδ2 T cells have anti-lymphoma effect in a mouse tumor model.
Duault C; Betous D; Bezombes C; Roga S; Cayrol C; Girard JP; Fournié JJ; Poupot M
Eur J Immunol; 2017 Dec; 47(12):2137-2141. PubMed ID: 28741710
[TBL] [Abstract][Full Text] [Related]
32. [Bcl-2 associated athanogene 3 affects the epithelial-mesenchymal transition in human cervical cancer].
Wei L; Qin XP; Zhao XX; Wang W
Zhonghua Fu Chan Ke Za Zhi; 2017 Aug; 52(8):551-557. PubMed ID: 28851173
[No Abstract] [Full Text] [Related]
33. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
[TBL] [Abstract][Full Text] [Related]
34. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.
Niu C; Jin H; Li M; Xu J; Xu D; Hu J; He H; Li W; Cui J
BMC Immunol; 2015 Oct; 16():61. PubMed ID: 26458364
[TBL] [Abstract][Full Text] [Related]
35. Metformin combined with nelfinavir induces SIRT3/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice.
Xia C; He Z; Liang S; Chen R; Xu W; Yang J; Xiao G; Jiang S
Eur J Pharmacol; 2019 Apr; 848():62-69. PubMed ID: 30695683
[TBL] [Abstract][Full Text] [Related]
36. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
37. Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes.
Lai D; Wang F; Chen Y; Wang C; Liu S; Lu B; Ge X; Guo L
Cancer Immunol Immunother; 2012 Jul; 61(7):979-89. PubMed ID: 22120758
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded γδ T cells or αβ T cells.
Deng X; Terunuma H; Terunuma A; Takane T; Nieda M
Int Immunopharmacol; 2014 Oct; 22(2):486-91. PubMed ID: 25131561
[TBL] [Abstract][Full Text] [Related]
39. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
